Items Tagged ‘Stage IV/Metastatic Bladder Cancer’

June 8th, 2016

Tecentriq® Approved for Bladder Cancer

By

The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor, and is the first agent in this class to be approved for the treatment of bladder cancer. Urothelial carcinoma (formerly known as transitional cell carcinoma) is […]

View full entry

Tags: atezolizumab, Bladder Cancer, inhibitor, News, PD-1, PD-L1, Stage IV/Metastatic Bladder Cancer, Tecentriq, urothelial carcinoma


June 8th, 2016

Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer

By

The immunotherapy agent Tecentriq® (atezolizumab) provides anti-cancer activity when used as initial therapy among patients with advanced bladder cancer who are not able to tolerate standard therapy. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Bladder cancer will be diagnosed in approximately 77,000 people in […]

View full entry

Tags: advanced, atezolizumab, Bladder Cancer, elderly, immunotherapy Tecentriq, News, smokers, Stage IV/Metastatic Bladder Cancer, urothlial carcinoma


March 16th, 2015

Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer

By

The treatment combination of Cyramza® (ramucirumab) plus Taxotere® (docetaxel) appears to extend progression-free survival in patients with advanced bladder cancer that has relapse after previous treatment. These findings were presented at the 2015 Genitourinary Cancers Symposium on February 26–28 in Orlando, Florida. Bladder cancer is diagnosed in roughly 50,000 men and 17,000 women annually in […]

View full entry

Tags: Bladder Cancer, cyramza, News, Recurrent Bladder Cancer, Stage IV/Metastatic Bladder Cancer, taxotere


June 23rd, 2014

Survival Benefit with Immediate Adjuvant Chemotherapy in Invasive Bladder Cancer

By

Results from a recent Phase III clinical trial suggest that patients with invasive bladder cancer may benefit from treatment with immediate adjuvant chemotherapy. These finding were presented at the 2014 American Society of Clinical Oncology (ASCO) meeting held in Chicago, May 31–June 3. Patients with Stage III, or invasive, bladder cancer have cancer that invades […]

View full entry

Tags: Bladder Cancer, News, Recurrent Bladder Cancer, Stage III Bladder Cancer, Stage IV/Metastatic Bladder Cancer, Stages II-III Bladder Cancer, surgery


June 12th, 2014

Experimental Drug Shows Promise for Treatment of Metastatic Bladder Cancer

By

According to results of a Phase I trial presented at the 2014 annual meeting of the American Society of Clinical Oncology, an investigative drug, MPDL3280A, demonstrates promise for the treatment of PD-L1 positive metastatic bladder cancer. Bladder cancer is diagnosed in roughly 50,000 men and 17,000 women annually in the United States. Bladder cancer is the […]

View full entry

Tags: Bladder Cancer, MPDL3280A, News, PD-L1, Recurrent Bladder Cancer, Stage IV/Metastatic Bladder Cancer


January 24th, 2013

Robotic Bladder Cancer Surgery Safe and Effective

By

Robotic-assisted surgery for invasive bladder cancer is effective and results in less bleeding and shorter hospital stays when compared to the traditional open procedure, according to the results of a study published in the Journal of Urology. The bladder is a hollow organ located in the pelvis. Its primary function is to store urine. The bladder […]

View full entry

Tags: Bladder Cancer, News, Recurrent Bladder Cancer, Stage III Bladder Cancer, Stage IV/Metastatic Bladder Cancer, Stages 0-I Bladder Cancer, Stages II-III Bladder Cancer


April 30th, 2012

Adding Chemotherapy to Radiation Reduces Bladder Cancer Recurrence

By

Chemotherapy plus radiation reduces the risk of recurrence in muscle-invasive bladder cancer patients by nearly 50% compared to radiation alone, according to the results of a study published in the New England Journal of Medicine.[1] Bladder cancer is diagnosed in roughly 50,000 men and 17,000 women annually in the United States. Patients with T2-T4a bladder cancer […]

View full entry

Tags: Bladder Cancer, News, Stage IV/Metastatic Bladder Cancer, Stages II-III Bladder Cancer, Urology


June 14th, 2011

Liposomal Cisplatin Safe for Patients with Renal Insufficiency

By

Liposomal cisplatin (Nanoplatin®), a chemotherapy drug still in clinical trials, does not cause damage to the kidneys and appears to provide at least equal anti-cancer effects as cisplatin (Platinol®) among cancer patients with renal insufficiency.  These results were recently presented at the 2011 annual meeting of the American Society of Clinical Oncology. Cisplatin (Platinol®) is […]

View full entry

Tags: Bladder Cancer, Lung Cancer - Non-Small Cell, News, Stage IV/Metastatic Bladder Cancer, Stages I-IIIA Lung Cancer - Non-Small Cell, Stages II-III Bladder Cancer, Stages IIIB-IV Lung Cancer - Non-Small Cell